Organ-on-a-chip (OOC) technologies are now being used across a range of drug discovery applications, through efficacy and into safety assessment. As the technology and applications evolve, new questions and opportunities are arising in terms of regulatory acceptance, cost efficiency, and model confidence through standardization.

In this GEN Learning Lab, CN Bio’s CSO Tomasz Kostrzewski, PhD, and toxicology consultant Clive Roper, PhD, will discuss all things OOC, including current applications, the evolving perspective of regulators, and ongoing efforts to harness OOCs’ potential in biomedicine.

Key questions addressed during the webinar include:

• How OOC is transforming drug discovery with its predictive and cost-effective approach.
• Discover how OOC tackles rising costs and prepares for the complexities of new drug modalities.
• Reduction and refinement of animal use while maintaining scientific rigor.
• Current industry challenges and how OOC providers are working to overcome them.
• Regulatory acceptance status, including the regulator’s viewpoint on OOC and ongoing efforts to support increased use.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.

Broadcast Date: March 20, 2024
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Pancreatic cancer is a complex disease with few treatment options and poor prognosis, in part due to the dearth of suitable models for studying its progression and assessing patients’ response to therapy. Interest in patient-derived organoids for the treatment of pancreatic cancer is growing because organoids better recapitulate the complexity and population diversity of patients as compared to more traditionally used cell lines. A major hurdle to executing these models is the challenging method used to culture organoids which often consists of maintaining organoids in domes of extracellular matrices (ECMs). These ECMs are viscous and temperature sensitive which can present challenges when used in conjunction with automated liquid handling systems.  

In this GEN Learning Lab, our speakers will discuss an alternative technique for maintaining organoids in Corning^® Elplasia^® microplates using media supplemented with Corning Matrigel^® matrix. During the event, you’ll learn about applications of patient-derived organoids to pancreatic cancer cases including examples that showcase the value of using these models to assess patients’ responses to treatment. You’ll also hear examples of how organoids’ predictive power is robust and consistent across passage, different sources and lots of basement membrane extract.

A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.

Originally Aired: November 17, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Many approved, full-length antibodies are of the immunoglobulin G (IgG) type, specifically IgG1, IgG2, or IgG4 subclasses. However, emerging non-traditional antibody formats are more efficacious and capable of reaching new targets, including crossing the blood–brain barrier. Formats that retain the basic structure of an IgG may inherit their pharmacokinetic properties, but novel constructs that lack the fragment crystallizable region (Fc) region of the antibody can have shorter half-lives. In therapeutics, smaller antibody formats such as single-chain fragment variables (scFv), nanobodies, or other scaffolds that can reach hidden targets or act as intrabodies to target intracellular antigens must strike a balance between efficacy and half-life.

In this GEN Learning Lab, Anna Moberg will discuss applications for screening and characterizing antibody and antibody fragments in pure or complex samples. During her presentation, she will introduce the Cytiva Biacore system, which uses surface plasmon resonance (SPR), a label-free and biophysical technology for characterizing antibodies. Mrs. Moberg will discuss how the technology can be used to monitor and track molecular interactions in real-time for drug discovery, quality control, and drug release testing.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelist.

Panelists:

Panelists:

Originally Aired: October 13, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Three-dimensional (3D) cultures such as spheroids and organoids are an important part of the research model market, helping to close the gap between cell cultures and animal models. Both organoids and spheroids have been used to create in vivo-like tissue models of cancer subtypes to study novel therapies and to make models for tissue engineering and regenerative medicine studies. But there are some key differences, with important implications for various applications. The right tool for a project is not always obvious. For spheroids and organoids, knowing where the cultures are similar and where they differ will help scientists select the best resource for their projects the first time around.

In this Learning Lab, Hilary Sherman, a Senior Scientist in the Corning Life Sciences Applications Lab, and Robert Padilla, a Field Application Scientist at Corning, dive into the topic of 3D culture techniques and why these technologies should be a part of any researcher’s repertoire. They will discuss the differences between spheroids and organoids, where they can be used, and the pros and cons of each culture type. They will also review customer case studies that exemplify the benefits of each culture type. And our speakers will offer tips for choosing the best models.

 

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.

Originally Aired: June 14, 2023
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

Multiplex immunofluorescence technologies have the potential to accelerate the development of more predictive biomarker panels. For clinical applications, high-quality images and robust image analysis are essential, as well as high sample throughput and simple workflows.  Therefore, understanding compromises made by different types of mIF and image analysis platforms is important for choosing the right technology.

In this Learning Lab, we speak with Ania Mikucki, Senior Tissue Analysis Scientist and Je Lee, Director of Innovation at Ultivue.  We will address barriers and potential solutions for clinical deployment of mIF, and briefly describe current methods and workflows with examples.

A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.

Produced with support from:

Je H. Lee
Director of Innovation
Ultivue, Inc.

Ania Mikucki
Senior Tissue Analysis Scientist
Ultivue, Inc.

---

Produced with support from:

---

Produced with support from:

---

Produced with support from: